Combined serotonin‐5‐HT2 and dopamine‐D2 antagonism in schizophrenia: Clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidone (R 64 766)
- 1 September 1990
- journal article
- research article
- Published by Wiley in Human Psychopharmacology: Clinical and Experimental
- Vol. 5 (3) , 225-231
- https://doi.org/10.1002/hup.470050307
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64 766) in the treatment of chronic psychosis: An open dose-finding studySchizophrenia Research, 1989
- Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patientsPsychopharmacology, 1989
- Remoxipride in schizophreniaActa Psychiatrica Scandinavica, 1986
- Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin‐S2 receptor blockerDrug Development Research, 1986
- Psychotropic properties of oxytocinNeuroscience and Behavioral Physiology, 1986
- Antipsychotic effect of remoxipride, a new substituted benzamide with selective antidopaminergic activityActa Psychiatrica Scandinavica, 1986
- Neuropeptide Therapies in Chronic Schizophrenia: TRH and Vasopressin AdministrationNeuropsychobiology, 1986
- The inhibitory GABAergic influence on striatal serotonergic neurons depends upon the habenulo-raphe pathwaysBrain Research, 1984
- Positive and Negative Schizophrenic Symptoms and the Role of DopamineThe British Journal of Psychiatry, 1980
- Assessment of drugs in schizophrenia. Asessment of drug‐induced extrapyramidal reactions and of drugs given for their control.British Journal of Clinical Pharmacology, 1976